Metastatic Cutaneous Melanoma Clinical Trials

6 recruiting

Metastatic Cutaneous Melanoma Trials at a Glance

6 actively recruiting trials for metastatic cutaneous melanoma are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Seattle, Columbus, and Ames. Lead sponsors running metastatic cutaneous melanoma studies include Emory University, EuroCityClinic LLC, and Fred Hutchinson Cancer Center.

Browse metastatic cutaneous melanoma trials by phase

Treatments under study

About Metastatic Cutaneous Melanoma Clinical Trials

Looking for clinical trials for Metastatic Cutaneous Melanoma? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Cutaneous Melanoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Cutaneous Melanoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Not Applicable

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8+1 more
Ohio State University Comprehensive Cancer Center60 enrolled1 locationNCT06391099
Recruiting
Phase 1

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell Carcinoma+22 more
Fred Hutchinson Cancer Center25 enrolled1 locationNCT05098210
Recruiting
Phase 2

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Urothelial CarcinomaEsophageal CarcinomaHepatocellular Carcinoma+28 more
Mayo Clinic50 enrolled1 locationNCT06265285
Recruiting
Phase 2

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Acral MelanomaMetastatic Cutaneous Melanoma+7 more
Emory University99 enrolled2 locationsNCT07155317
Recruiting
Phase 2

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8+4 more
SWOG Cancer Research Network112 enrolled331 locationsNCT04511013
Recruiting
Phase 2

Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

Metastatic Cutaneous MelanomaMetastatic Non-small Cell Lung Cancer (NSCLC)
EuroCityClinic LLC90 enrolled1 locationNCT07130032